Samphire Neuroscience secures $2.3m in pre-seed funding to launch Nettle wearable
The pre-seed round will fund clinical research and regulatory approval for the company's neurostimulation headband.
Samphire Neuroscience is a medical technology company developing a neurotechnology wearable designed to manage menstrual pain and premenstrual syndrome.
Samphire Neuroscience has raised $2.3m in pre-seed funding to commercialise its neurotechnology wearable, Nettle, aimed at providing a drug-free remedy for menstrual pain and premenstrual syndrome. The investment round attracted backing from SOSV, FIRSTPICK, Afterwork, Seaside, Ayuh, CVX Ventures, Dr Pamela Walker, and Rowena Ironside.
The capital will be directed towards advancing clinical research and securing regulatory approval for the medical-grade headband. Nettle applies transcranial direct current stimulation to the prefrontal and motor cortices to manage both the emotional and physical symptoms associated with the menstrual cycle.
Co-founded by Emilė Radytė and Alex Cook, the London-based enterprise seeks to address long-standing gaps in female healthcare by targeting the brain as the central node of wellbeing.
From the founder
"Women’s health has been notoriously under-researched and underfunded for decades,"
Emilė Radytė
CEO and Co-Founder at Samphire Neuroscience
Investor perspective
"I have spent my career investing in mental health solutions, and was struck by how unique Samphire’s approach is,"
Duncan Turner
General Partner, SOSV
Use of funds
- 01Fund research and development
Investors
Categories
About the company
Samphire Neuroscience
Medical technology company developing wearable solutions for women's health.